Literature DB >> 15075442

Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia.

Takahiro Shinkai1, Osamu Ohmori, Chima Matsumoto, Hiroko Hori, James L Kennedy, Jun Nakamura.   

Abstract

Possible involvement of oxidative stress in the pathophysiology of tardive dyskinesia (TD) has been proposed. Long-term administration of neuroleptics alters dopaminergic turnover, yielding the increase of the formation of reactive oxygen species (ROS), which may lead to TD through neuronal toxicity as a consequence of oxidative stress. In the present study, the relationship between TD and a polymorphism of the neuronal nitric oxide synthase (NOS1) gene whose reaction product, nitric oxide (NO), is involved in oxidative stress was studied in 171 Japanese patients with schizophrenia, including 41 patients meeting TD criteria. The C/T polymorphism in exon 29 of the NOS1 gene was genotyped using polymerase chain reaction (PCR) amplification followed by restriction enzyme digestion. No significant difference in genotype frequencies was detected between subjects with and without TD (chi2 = 1.54, df = 2, p = 0.46). In addition, there was no difference in allele frequencies (chi2 = 0.42, df = 1, p = 0.51). These results suggest that the NOS1 gene polymorphism may not confer increased susceptibility to TD, although more investigations on other populations are warranted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075442     DOI: 10.1385/NMM:5:2:163

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  53 in total

Review 1.  Central actions of nitric oxide in regulation of autonomic functions.

Authors:  T L Krukoff
Journal:  Brain Res Brain Res Rev       Date:  1999-07

2.  Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase.

Authors:  D S Bredt; P M Hwang; C E Glatt; C Lowenstein; R R Reed; S H Snyder
Journal:  Nature       Date:  1991-06-27       Impact factor: 49.962

3.  Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.

Authors:  R H Segman; U Heresco-Levy; B Finkel; T Goltser; R Shalem; M Schlafman; A Dorevitch; A Yakir; D Greenberg; A Lerner; B Lerer
Journal:  Mol Psychiatry       Date:  2001-03       Impact factor: 15.992

4.  Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients.

Authors:  V M Steen; R Løvlie; T MacEwan; R G McCreadie
Journal:  Mol Psychiatry       Date:  1997-03       Impact factor: 15.992

5.  Impaired glucose tolerance and abnormal movements in patients with schizophrenia.

Authors:  S K Schultz; S Arndt; B C Ho; S E Oliver; N C Andreasen
Journal:  Am J Psychiatry       Date:  1999-04       Impact factor: 18.112

6.  Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia.

Authors:  H Hori; O Ohmori; T Shinkai; H Kojima; C Okano; T Suzuki; J Nakamura
Journal:  Neuropsychopharmacology       Date:  2000-08       Impact factor: 7.853

7.  The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism.

Authors:  ZhiJun Zhang; XiaoBin Zhang; Gang Hou; WeiWei Sha; Gavin P Reynolds
Journal:  J Psychiatr Res       Date:  2002 Sep-Oct       Impact factor: 4.791

8.  Biological determinants and risk factors for tardive dyskinesia in schizophrenia.

Authors:  R Sandyk
Journal:  Int J Neurosci       Date:  1993 Mar-Apr       Impact factor: 2.292

9.  gamma-Acetylenic GABA in tardive dyskinesia.

Authors:  D E Casey; J Gerlach; G Magelund; T R Christensen
Journal:  Arch Gen Psychiatry       Date:  1980-12

10.  Prolonged inhibition of brain nitric oxide synthase by short-term systemic administration of nitro-L-arginine methyl ester.

Authors:  C Iadecola; X Xu; F Zhang; J Hu; E E el-Fakahany
Journal:  Neurochem Res       Date:  1994-04       Impact factor: 3.996

View more
  7 in total

Review 1.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

2.  Nitric oxide synthase gene polymorphisms in functional dyspepsia.

Authors:  Jae Myung Park; Myong-Ki Baeg; Chul-Hyun Lim; Yu Kyung Cho; Myung-Gyu Choi
Journal:  Dig Dis Sci       Date:  2013-10-11       Impact factor: 3.199

Review 3.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

4.  Nitric oxide synthase-2 (NOS2) gene polymorphism c.1832C>T (Ser608Leu) associated with nitrosative stress in Fanconi anaemia.

Authors:  Merin George; Avani Solanki; Purvi Mohanty; Somprakash Dhangar; Aruna Rajendran; Sheila Mohan; Babu Rao Vundinti
Journal:  Mol Biol Rep       Date:  2021-03-28       Impact factor: 2.316

Review 5.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

Review 6.  Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Authors:  Evangelia Eirini Tsermpini; Sara Redenšek; Vita Dolžan
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

Review 7.  Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.

Authors:  Mujeeb U Shad
Journal:  Behav Sci (Basel)       Date:  2021-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.